SK bioscience to win new PAHO contract for varicella vaccine

28 February 2025

South Korean vaccine maker SK bioscience (KRX: 302440) today revealed that it has received prior notification from the Pan American Health Organization (PAHO), a specialized agency of the United Nations in charge of international health cooperation in the Americas, to supply its self-developed varicella (chickenpox) vaccine, SKYVaricella, to Latin America through 2027.

The firm made a foray into the Latin American market by providing 37.4 billion won ($25.6 million) worth of SkyVaricella vaccines for three years after winning its first order in the PAHO’s varicella vaccine bid in 2022.

SK bioscience did not reveal what the potential new -contract would be worth, but its shares fell 8.3% to 42,550 won following the announcement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK